argenx Sets New Standards in Immunology: Strategic Growth and Innovation in Autoimmune Disease Treatment

Leading the Transformation in Autoimmune Disease Treatment

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, has established itself as a pioneer in translating immunology breakthroughs into world-class novel antibody-based medicines through partnerships with leading academic researchers.

Strategic Vision and Financial Growth

The company is positioned to achieve profitability in 2025, while managing approximately $2.5 billion in marketing, administrative and R&D expenses. This milestone is largely driven by the strength of its indication-spanning FcRn inhibitor VYVGART.

The company has established ambitious strategic priorities under its Vision 2030, aiming to treat 50,000 patients globally with its medicines, secure 10 labeled indications across all approved medicines, and advance five pipeline candidates into Phase 3 development by 2030.

VYVGART Success and Expansion

VYVGART, their first-and-only IgG Fc-antibody fragment targeting the neonatal Fc receptor (FcRn), has achieved significant milestones with approvals in three indications: generalized myasthenia gravis (gMG) globally, primary immune thrombocytopenia (ITP) in Japan, and chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S., Japan, China, and the EU.

A key development anticipated in 2025 is the FDA’s April 10 target action date for the approval of a prefilled syringe version of VYVGART. This new format could allow patients to self-administer the treatment at home, unlike current formulations which require visits to a doctor’s office or infusion center followed by monitoring.

Research and Pipeline Development

The company’s robust R&D investments, which reached $328 million in Q2 2025, are focused on expanding efgartigimod across 15 severe autoimmune diseases, advancing empasiprubart studies in various conditions, and developing ARGX-119 through proof-of-concept studies in ALS, CMS, and SMA.

Looking Ahead

The company has raised the bar in terms of both safety and efficacy in treating autoimmune conditions, particularly in MG. Their commitment to engineering life-changing immunology solutions continues to be driven by the resilient spirit of patients and the urgency to deliver innovative treatments.